Plain language summary
Conflicting reports exist on the role of gastrointestinal microorganisms in the development of obesity. The consumption of avocados has been associated with lower body weight, increased feelings of being full and lower blood lipid concentrations. This randomised controlled trial of 163 adults aimed to determine the effect of 12 weeks of daily avocado intake on the gut microbiota and the by-products they produce. The results showed that the regular consumption of avocados resulted in greater abundances of gut bacteria capable of fibre fermentation and altered the by-products produced. Faecalibacterium, Lachnospira and Alistipes bacteria were all increased. However it should be noted that the individuals in the avocado group were also given a meal plan higher in fibre. It was concluded that avocados can alter gut microbiota composition and metabolic function of the gut. This study could be used by healthcare professionals to understand that nutrient dense foods may have the ability to alter metabolic functions in the gut, however further research is needed to determine whether avocado consumption is of benefit to those with obesity.
Abstract
BACKGROUND Avocados are rich in dietary fiber and monounsaturated fatty acids (MUFAs), nutrients that have been independently connected to metabolic health benefits and the gastrointestinal microbiota. OBJECTIVES We aimed to evaluate the impact of avocado consumption on the gastrointestinal microbiota and microbial metabolites, secondary outcomes of the Persea americana for Total Health (PATH) study, and conduct exploratory analyses to assess relations between the fecal microbiota, fecal metabolites, and health markers. METHODS Adults [n = 163, 25-45 y, BMI (kg/m2) ≥ 25.0] were enrolled in the PATH study, a 12-wk investigator-blinded trial where participants were batch randomized to match the 2 groups by age, sex, visceral adiposity, and fasting glucose concentrations. Participants consumed isocaloric meals with or without avocado (175 g, men; 140 g, women) once daily for 12 wk. The fecal microbiota was assessed with 16S ribosomal RNA gene (V4 region) sequencing and analysis using DADA2 and QIIME2. Fecal fatty acid and bile acid concentrations were quantified using GC and LC-MS. Per-protocol (≥80% meal consumption) and intent-to-treat analyses were conducted using univariate ANOVA and Mann-Whitney U tests. Bivariate correlations were conducted between fecal microbiota, fecal metabolites, and health measures. RESULTS The avocado treatment increased ɑ diversity and enriched Faecalibacterium, Lachnospira, and Alistipes between 26% and 65% compared with the control group. The avocado group had 18% greater fecal acetate, 70% greater stearic acid, and 98% greater palmitic acid concentrations than the control group, while the concentrations of the bile acids cholic and chenodeoxycholic acid were 91% and 57% lower, respectively. CONCLUSIONS Daily avocado consumption resulted in lower fecal bile acid concentrations, greater fecal fatty acid and SCFAs, and greater relative abundances of bacteria capable of fiber fermentation, providing evidence that this nutrient-dense food affects digestive physiology, as well as the composition and metabolic functions of the intestinal microbiota. This trial was registered at www.clinicaltrials.gov as NCT02740439.
Methodological quality
Jadad score
:
3
Allocation concealment
:
No
